Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COVI-DOSE
2020-001709-21Phase 4Completed
- Sponsor
- CHRU Nancy
- Start
- Apr 2020
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of enoxaparin, tinzaparin, dalteparin and nadroparin in coronavirus disease 2019 (COVID-19) and venous thromboembolism (VTE) (2 arms), sponsored by CHRU Nancy. Started Apr 2020; status: completed.
02
Drugs
enoxaparintinzaparindalteparinnadroparin
03
Conditions
coronavirus disease 2019 (COVID-19)venous thromboembolism (VTE)
Beyond the preview
Go deeper on 2020-001709-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001709-21.